# Early Cancer Detection

3 related articles

Subscribe to updates

Genome Medicine Oct 15, 2026
Methylation sequencing also carries fragmentomics: plasma cfDNA blocks give cancer tests an interpretable second signal
Plasma cell-free DNA methylation sequencing, long used only to read methylation, is shown to partially retain fragmentomic signals such as fragment length and end motifs. The study delineates co-methylated blocks directly in plasma cfDNA, places methylation and fragmentomic features in the same genomic intervals, and builds an interpretable ensemble model for cancer detection and tissue-of-origin prediction. Cross-platform comparisons show major fragmentomic patterns are recapitulated in methylation sequencing, though preservation varies by feature.
Plasma cell-free DNA methylation sequencing, long used only to read methylation, is shown to partially retain fragmentomic signals such as fragment length and end motifs. The study delineates co-methylated blocks directly in plasma cfDNA, places methylation and fragmentomic features in the same genomic intervals, and builds an interpretable ensemble model for cancer detection and tissue-of-origin prediction. Cross-platform comparisons show major fragmentomic patterns are recapitulated in methylation sequencing, though preservation varies by feature.
Sun Yat-sen University Eighth Affiliated Hospital of Sun Yat-sen University Huazhong Agricultural University
Yunze Wang（First author）Wen Zhang（Corresponding author）Qingjiao Li（Corresponding author）Xionghui Zhou（Corresponding author）
FAME cfDNA fragmentomics Methylation haplotype blocks Early Cancer Detection
Nature News Oct 2, 2026
Pancreatic cancer interception gains support from a newly approved drug and mouse evidence, as PRECEDE enrolls over 12,000 people
This Nature report surveys the latest progress in pancreatic cancer interception: after the FDA approved daraxonrasib (Rasonque) in August, the AACR pancreatic cancer meeting made interception a main theme, Simeone reported that PRECEDE has enrolled a little more than 12,000 people with more than 50 participants diagnosed with pancreatic cancer, many at the earliest stages, and set a goal of raising five-year survival from 13.7% to 50%, while Stanger's team showed in mice that giving a drug that disarms KRAS and related cancer-promoting proteins when tiny precancerous pancreatic growths appear improved survival.
This Nature report surveys the latest progress in pancreatic cancer interception: after the FDA approved daraxonrasib (Rasonque) in August, the AACR pancreatic cancer meeting made interception a main theme, Simeone reported that PRECEDE has enrolled a little more than 12,000 people with more than 50 participants diagnosed with pancreatic cancer, many at the earliest stages, and set a goal of raising five-year survival from 13.7% to 50%, while Stanger's team showed in mice that giving a drug that disarms KRAS and related cancer-promoting proteins when tiny precancerous pancreatic growths appear improved survival.
University of Pennsylvania University of California San Diego
Cancer Interception Early Cancer Detection Daraxonrasib
Nanoscale Sep 17, 2026
Programmable nanoprobes for molecular imaging of cancer: toward adaptive and context-responsive diagnostics
This review surveys the design principles and functional architectures of stimuli-responsive nanoprobes, noting that they can achieve context-responsive activation and signal modulation in response to endogenous tumor cues (acidic pH around 6.5-6.8, glutathione at 2-10 mM, enzymatic overexpression, hypoxia below 2% O2, and redox gradients) and exogenous triggers (near-infrared light at 700-1000 nm, magnetic fields, and ultrasound), yielding 5-20-fold signal amplification, and that they can be integrated with multimodal imaging and artificial intelligence for real-time data interpretation and adaptive diagnostics.
This review surveys the design principles and functional architectures of stimuli-responsive nanoprobes, noting that they can achieve context-responsive activation and signal modulation in response to endogenous tumor cues (acidic pH around 6.5-6.8, glutathione at 2-10 mM, enzymatic overexpression, hypoxia below 2% O2, and redox gradients) and exogenous triggers (near-infrared light at 700-1000 nm, magnetic fields, and ultrasound), yielding 5-20-fold signal amplification, and that they can be integrated with multimodal imaging and artificial intelligence for real-time data interpretation and adaptive diagnostics.
University of the Basque Country Saveetha University Hebei University of Technology Assam Down Town University Brown University
Arnabjyoti Deva Sarma（First author）
Stimuli-Responsive Nanoprobes Molecular Imaging Early Cancer Detection

You’re all caught up

Methylation sequencing also carries fragmentomics: plasma cfDNA blocks give cancer tests an interpretable second signal

Pancreatic cancer interception gains support from a newly approved drug and mouse evidence, as PRECEDE enrolls over 12,000 people

Programmable nanoprobes for molecular imaging of cancer: toward adaptive and context-responsive diagnostics